News - VEGFA-L - LARVOL VERI

Expression Profiles of Integrin-Linked Kinase, Vascular Endothelial Growth Factor A, and Ephrin Type-A Receptor 2 in Colorectal Cancer Lymph Nodes. (PubMed, Cureus)

Additionally, the group with low VEGFA expression was statistically significantly higher (p=0.01) compared to the negative control. Conclusion The expression levels of EphA2, ILK, and VEGFA were found to be higher in LNs with lymphatic invasion compared to those with negative expression, highlighting the role of these proteins in CRC progression.

1 month ago

Journal

VEGFA (Vascular endothelial growth factor A) • EPHA2 (EPH receptor A2)

VEGFA expression • VEGFA-L

1year

Metformin Regulates the miR-205/VEGFA Axis in Renal Cell Carcinoma Cells - Exploring a Clinical Synergism with Tyrosine Kinase Inhibitors. (PubMed, Urol Int)

Our results support the protective role of MF in ccRCC and offer functional insights into the clinical synergism with tyrosine kinase inhibitors (TKI).

1 year ago

Journal

VHL (von Hippel-Lindau tumor suppressor) • MIR205 (MicroRNA 205)

VEGFA expression • VEGFA-L

sunitinib • Inlyta (axitinib) • metformin

1year

Knockdown of NUPR1 inhibits angiogenesis in lung cancer through IRE1/XBP1 and PERK/eIF2α/ATF4 signaling pathways. (PubMed, Open Med (Wars))

Furthermore, the knockdown of NUPR1 may reduce angiogenesis by lowering VEGFA expression through inositol-requiring enzyme 1 (IRE1)/X box binding protein 1 (XBP1) and protein kinase RNA-like endoplasmic reticulum kinase (PERK)/eukaryotic translation initiation factor 2 A (eIF2α)/recombinant activating transcription factor 4 (ATF4) signaling pathways in A549 or H1299 cells. In conclusion, these findings demonstrated that NUPR1 knockdown inhibits angiogenesis in A549 and H1299 cells through IRE1/XBP1 and PERK/eIF2α/ATF4 signaling pathways, indicating that NUPR1 could represent a novel lung cancer therapeutic target.

1 year ago

Journal

ATF4 (Activating Transcription Factor 4) • ERN1 (Endoplasmic Reticulum To Nucleus Signaling 1) • XBP1 (X-box-binding protein 1) • TCF4 (Transcription Factor 4)

VEGFA expression • VEGFA-L

over1year

Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced EGFRnon-small-cell lung cancer. (PubMed, Transl Lung Cancer Res)

No valid results were obtained in 13 polymorphisms of eight genes. EB treatment showed better treatment outcomes in patients with low pVEGFA and serum leptin, and limited efficacy in patients with high serum follistatin.

over 1 year ago

P2 data • Journal • Metastases

EGFR (Epidermal growth factor receptor) • LEP (Leptin)

EGFR mutation • EGFR positive • VEGFA-L

Avastin (bevacizumab) • erlotinib

over1year

Spatial-Omics pipeline to aid personalization of precision medicine in metastatic recurrent Head & Neck Cancers. (EACR 2023)

Patient's primary oral tumor responded to chemo-radio therapy, followed by nivolumab...Lastly, the compassion between pembrolizumab + lenvatinib responsive (MAR22) and non-responsive (SEP22) OPSCCs showed shared CL4-5 phenotypes with PD-1/PD-L1low and VEGFAhigh expression, suggesting that SEP22 treatment failure could be linked to the reduction of Lenvatinib dose instead of a drug resistance mechanism. ConclusionWe demonstrated the appropriateness of Spatial Omics as a medical tool for recapitulating patient disease and aiding in the personalized drug selection processes. The use of L/R interactions and pathway analysis provides a scientific-based rationale for drug selection, allowing the prioritization of targets.

over 1 year ago

PD(L)-1 Biomarker • IO biomarker • Metastases

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • NRP1 (Neuropilin 1) • SNAI2 (Snail Family Transcriptional Repressor 2) • SOX4 (SRY-Box Transcription Factor 4)

PD-L1 expression • PD-L1 overexpression • VEGFA-L • PD-L1-L

Keytruda (pembrolizumab) • Opdivo (nivolumab) • Lenvima (lenvatinib)

2years

The role of pericytes on the efficacy of bevacizumab in colorectal cancer. (PubMed, Turk J Med Sci)

Our results suggested that bevacizumab may be more effective in patients having less vascular density in the tumor tissue. But further studies are needed to support this finding.

2 years ago

Journal

CD34 (CD34 molecule) • CSPG4 (Chondroitin Sulfate Proteoglycan 4) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)

CD34 positive • VEGFA expression • VEGFA-L

Avastin (bevacizumab)

2years

Systematic Analysis of CXC Chemokine-Vascular Endothelial Growth Factor A Network in Colonic Adenocarcinoma from the Perspective of Angiogenesis. (PubMed, Biomed Res Int)

This study revealed that the CXC chemokine-VEGFA network might act as a prognostic biomarker for patients with COAD. Moreover, our study provides new therapeutic targets for COAD, serving as a reference for further research in the future.

2 years ago

Journal • BRCA Biomarker

ER (Estrogen receptor) • BRCA1 (Breast cancer 1, early onset) • VEGFA (Vascular endothelial growth factor A) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • EP300 (E1A binding protein p300) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • CXCL11 (C-X-C Motif Chemokine Ligand 11) • HDAC2 (Histone deacetylase 2) • MIR221 (MicroRNA 221) • ATF4 (Activating Transcription Factor 4) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • MIR199A (MicroRNA 199a) • MIR210 (MicroRNA 210) • MIR381 (MicroRNA 381) • XBP1 (X-box-binding protein 1) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • CXCL3 (C-X-C Motif Chemokine Ligand 3) • EGR1 (Early Growth Response 1) • MIR218 (MicroRNA 218) • MIR486-1 (MicroRNA 486-1) • RELA (RELA Proto-Oncogene)

CXCL12 expression • VEGFA expression • VEGFA-L • CXCL8 expression

over2years

Network Pharmacology and Molecular Docking Validation to Reveal the Pharmacological Mechanisms of Kangai Injection against Colorectal Cancer. (PubMed, Biomed Res Int)

Network pharmacology intuitively showed the multicomponent, multiple targets, and multiple pathways of Kangai injection in the treatment of CRC. The molecular docking experiment verified that compounds of Kangai injection had good binding ability with top 10 hub target proteins as well.

over 2 years ago

Journal

EGFR (Epidermal growth factor receptor) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • STAT3 (Signal Transducer And Activator Of Transcription 3) • HDAC1 (Histone Deacetylase 1) • MMP9 (Matrix metallopeptidase 9) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)

VEGFA-L

3years

System analysis of VEGFA in renal cell carcinoma: The expression, prognosis, gene regulation network and regulation targets. (PubMed, Int J Biol Markers)

This study revealed VEGFA expression and potential gene regulatory network in patients with renal cell carcinoma, thereby laying a foundation for further research on the role of VEGFA in renal cell carcinoma occurrence. Moreover, the study provides new renal cell carcinoma therapeutic targets and prognostic biomarkers as a reference for fundamental and clinical research.

3 years ago

Journal

ER (Estrogen receptor) • CD8 (cluster of differentiation 8) • VEGFA (Vascular endothelial growth factor A) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • FLT1 (Fms-related tyrosine kinase 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CD4 (CD4 Molecule) • MIR21 (MicroRNA 21) • NOTCH4 (Notch 4) • AURKB (Aurora Kinase B) • ETS1 (ETS Proto-Oncogene 1) • FOXO3 (Forkhead box O3) • CDK1 (Cyclin-dependent kinase 1) • RRAGD (Ras related GTP binding)

VEGFA overexpression • VEGFA expression • VEGFA-L